Clinical Verification of Peptide Biomarkers for Human Aging

NCT02166307 | Completed DMC

• 1 other identifier: deng02
• Study Type: observational
• Target: 253
• Locations: 0 countries
• Sites: N/A

Brief Summary

Aging in human physically refers to a multidimensional process that all the changes were accumulated in a person over time. These aging changes are responsible for the progressive increases in the chance of disease and death associated with them. So far, there are several theories have been developed to understand the aging process, such as cross-linking, which is led by Maillard Reactions. Maillard Reaction is a complex series of reactions between reducing sugar/aldehydes and amino groups on proteins. Under physiological conditions, aldehydes are products of various exogenous and endogenous amines catalyzed by semicarbazide-sensitive amine oxidase (SSAO), a family of heterogeneous enzyme. It was reported that SSAO shows a significant higher catalytic activity, producing more aldehydes in age-related diseases. However, SSAO is not a perfect candidate to be monitored for evaluating aging, because it is widely distributed in tissues, which are not readily accessible sample-sources for clinical applications. In this work, the investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

Conditions

Aging

Keywords

formaldehyde; Maillard Reaction; cross-linkage; human aging

Outcome Measures

Primary Outcomes (1)

• measurement of the amount of plasma peptides

  The investigators have found 6 biomarker candidates by developing a standard-free, label-free MS-based proteomics method based on standard protein (human serum albumin, the highest abundance protein in human plasma) model in vitro. Then, the investigators wanted to verify these biomarker candidates by clinical plasma samples to see if there is significant quantitative difference among people with different ages.

  two years

Eligibility Criteria

• Age: 23 Years - 72 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

university hospital, plasma samples of physical examination, faculties and staff of a certain university

You may qualify if:

• Cases with different ages

You may not qualify if:

• Cases with Diabetes Mellitus and Hepatitis B

Sponsors & Collaborators

• Beijing Institute of Technology: lead

Study Officials

• Yulin Deng, Ph.D

  School of Life Science, BIT

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dean of School of Life Science

Study Record Dates

• First Submitted: June 16, 2014
• First Posted: June 18, 2014
• Study Start: January 1, 2009
• Primary Completion: December 1, 2011
• Study Completion: December 1, 2011
• Last Updated: June 18, 2014

Record last verified: 2014-06